Fig. 1
From: Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant
Development and characterization of the FNP-Fc-RBDOmicron vaccine against SARS-CoV-2 Omicron variant. a Schematic representation of a SARS-CoV-2 Omicron RBD with Fc tag (light green), a ferritin-based 24-meric nanoparticle with N-terminal protein A tag (green), and an FNP-Fc-RBDOmicron complex. b The FNP complex was analyzed by SDS-PAGE. c Size distribution of the FNP complex was detected by DLS. d, e Interaction between Fc-RBDOmicron and FNP was detected by ELISA and SPR. An equal amount of ovalbumin served as a control. The data are presented as mean ± S.E.M. Statistical significance was calculated via ordinary unpaired parametric t test. f The FNP-Fc-RBDOmicron complex was analyzed by SDS-PAGE. g Size distribution of the FNP-Fc-RBDOmicorn was detected by DLS. h, i Measurement of IgG and neutralizing antibodies induced in immunized mice. The mice were immunized via intramuscular (i.m.) prime and boost at 2 weeks (10 μg per mouse, n = 5). Sera at 14 days post-2nd immunization were detected for RBDOmicron-specific IgG antibodies by ELISA. The neutralizing antibodies were assessed by live SARS-CoV-2 Omicron BA.1 virus. The data are presented as mean ± S.E.M. (n = 5). Statistical significance was calculated via one-way ANOVA with multiple comparisons test. j Inhibition potency of immunized sera on SARS-CoV-2 RBD-hACE2 binding in hACE2/HEK293T cells. The inhibition potency was evaluated by flow cytometry. Inhibition percentage (%) was calculated by a relative fluorescence intensity. k, l Splenocytes were stimulated with the RBD protein of Omicron. The IFN-γ and IL-4 secretion condition in splenocytes were detected by an ELISpot assay. Data represented as mean ± S.E.M. (n = 5). Statistical significance was calculated via ordinary unpaired parametric t test
